Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

20.4K
Here we describe a protocol for multiplex fluorescent immunohistochemical staining and imaging for the simultaneous localization of multiple cancer-associated antigens in lymphoma. This protocol can be extended to the colocalization analysis of biomarkers within all tissue...
20.4K
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

10.4K
Here, we describe a combined flow cytometric cell sorting and low-input, next-generation library construction protocol designed to produce high-quality, whole-exome data from the Hodgkin Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma...
10.4K
Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models07:12

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

21.0K
Bioluminescence imaging is a well-known tool for localizing tumors and metastases, but quantification of these images often requires complex calculations and particular instruments. We describe the easy-to-use luminoscore method, based on precise acquisition conditions, requiring no calculations, and enabling tumor burden and treatment response to be monitored in mouse...
21.0K
Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

7.5K
Transgenic lck:eGFP zebrafish express GFP highly in T lymphocytes, and have been used to study T cell development and acute lymphoblastic leukemia. This line can be used to study B cells, which express lck at lower levels. This protocol describes purification of malignant and non-malignant B cells from lck:eGFP...
7.5K
Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy05:24

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy

759
This study introduces multifractal spectrum analysis for assessing pulmonary nodule malignancy. Using CT-DICOM data, the method calculates fractal dimensions across multiple voxel scales, revealing significant differences between early-stage and late-stage pulmonary...
759
The Use of Mixed Reality in Custom-Made Revision Hip Arthroplasty: A First Case Report07:45

The Use of Mixed Reality in Custom-Made Revision Hip Arthroplasty: A First Case Report

3.8K
A complex revision hip arthroplasty was performed using a custom-made implant and mixed reality technology. According to the authors' knowledge, this is the first report of such procedure described in the literature.
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

International journal of clinical oncology·2026
Same author

Histiocytic sarcoma with a common clonal origin emerged after 33 years from B-cell precursor acute lymphoblastic leukemia.

Journal of clinical and experimental hematopathology : JCEH·2026
Same author

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Journal of geriatric oncology·2026
Same author

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

The New England journal of medicine·2026
Same author

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.

International journal of clinical oncology·2026
Same author

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

International journal of hematology·2026

Related Experiment Video

Updated: Jan 19, 2026

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.4K

Revised staging system for malignant lymphoma based on the Lugano classification.

Wataru Munakata1, Takashi Terauchi2, Dai Maruyama1

  • 1Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Japanese Journal of Clinical Oncology
|September 11, 2019
PubMed
Summary

The updated Lugano classification simplifies lymphoma staging using advanced imaging. This revision streamlines disease evaluation and reduces the need for biopsies in certain lymphomas.

Keywords:
AJCCFDG-PET/CTLugano classificationmalignant lymphoma

More Related Videos

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.4K
Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
07:12

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

Published on: July 7, 2016

21.0K

Related Experiment Videos

Last Updated: Jan 19, 2026

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.4K
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.4K
Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
07:12

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

Published on: July 7, 2016

21.0K

Area of Science:

  • Oncology
  • Medical Imaging
  • Hematology

Background:

  • The 2014 Lugano classification updated recommendations for staging and evaluating malignant lymphomas.
  • This system was adopted by the American Joint Committee on Cancer's eighth edition staging manual.

Purpose of the Study:

  • To review the updated Lugano classification for malignant lymphomas.
  • To discuss the implications of revised staging and evaluation protocols.

Main Methods:

  • Adoption of fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as the standard imaging technique for staging FDG-avid histologies.
  • Simplified evaluation of lymph node and organ involvement (liver, spleen) using FDG-PET/CT.
  • Elimination of bone marrow biopsies for Hodgkin lymphoma and diffuse large B-cell lymphoma staging.

Main Results:

  • FDG-PET/CT is now the standard for staging FDG-avid lymphomas.
  • Organ involvement assessment is simplified.
  • Bone marrow biopsies can be omitted in specific lymphoma types.
  • Symptom designations (A/B) are now primarily relevant for Hodgkin lymphoma.

Conclusions:

  • The revised Lugano classification enhances lymphoma staging and patient management.
  • Standardized imaging protocols improve disease evaluation.
  • Streamlined procedures are expected to benefit clinical trial conduct.